IFRX
InflaRx N.V.
as of 04-10-2026 3:46pm EST
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Frequently Asked Questions
Learn more about our IFRX ML prediction model
What parameters are used to train the IFRX ML model?
Our stocks IFRX ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.
How often is the IFRX ML model updated?
We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.
Why might the model accuracy vary?
Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.
How can I contribute data to improve accuracy?
We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.
Are shorter timeframe predictions available?
Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.
Should I use this for financial decisions?
Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.
Share on Social Networks:
Disclaimer
Our IFRX ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"IFRX Forecast & Prediction for April 12, 2026 InflaRx N.V." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.